Search by Drug Name or NDC
NDC 60505-2521-03 cilostazol 50 mg/1 Details
cilostazol 50 mg/1
cilostazol is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Apotex Corp.. The primary component is CILOSTAZOL.
MedlinePlus Drug Summary
Cilostazol is used to reduce the symptoms of intermittent claudication (pain in the legs that worsens when walking and improves when resting that is caused by narrowing of the blood vessels that supply blood to the legs). Cilostazol is in a class of medications called platelet-aggregation inhibitors (antiplatelet medications). It works by improving blood flow to the legs.
Related Packages: 60505-2521-03Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Cilostazol
Product Information
| NDC | 60505-2521 |
|---|---|
| Product ID | 60505-2521_b0e1c8ca-e2f8-970d-74d1-5031794c6516 |
| Associated GPIs | 85155516000320 |
| GCN Sequence Number | 037979 |
| GCN Sequence Number Description | cilostazol TABLET 50 MG ORAL |
| HIC3 | M9P |
| HIC3 Description | PLATELET AGGREGATION INHIBITORS |
| GCN | 08603 |
| HICL Sequence Number | 017433 |
| HICL Sequence Number Description | CILOSTAZOL |
| Brand/Generic | Generic |
| Proprietary Name | cilostazol |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | cilostazol |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 50 |
| Active Ingredient Units | mg/1 |
| Substance Name | CILOSTAZOL |
| Labeler Name | Apotex Corp. |
| Pharmaceutical Class | Phosphodiesterase 3 Inhibitor [EPC], Phosphodiesterase 3 Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA077030 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 60505-2521-03 (60505252103)
| NDC Package Code | 60505-2521-3 |
|---|---|
| Billing NDC | 60505252103 |
| Package | 30 TABLET in 1 BOTTLE (60505-2521-3) |
| Marketing Start Date | 2011-10-18 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |